JPMorgan raised the firm’s price target on Syndax (SNDX) to $39 from $35 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target lowered to $42 from $45 at Citi
- Promising Outlook for Syndax Pharmaceuticals: Buy Rating Supported by Revuforj Launch and Strategic Positioning
- Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges
- Syndax Pharmaceuticals Reports 2024 Financial Results
- Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones